Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024年3月7日 - 6:05AM
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
nonalcoholic steatohepatitis (NASH), today announced that the
company granted equity awards to (i) Mardi C. Dier, the Company’s
new Senior Vice President and Chief Financial Officer, effective
March 11, 2024 and (ii) 39 other new employees, in each case with a
grant date of March 1, 2024, as equity inducement awards under the
terms of the company's 2023 Inducement Plan. The equity awards were
approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as inducement
material to Ms. Dier’s and the other employees’ acceptance of
employment with the company. Ms. Dier received options to purchase
13,353 shares of Madrigal’s common stock, 8,875 time-based
restricted stock units and 8,875 market-based performance stock
units (“MSUs”). The other new employees received, in the aggregate,
options to purchase 853 shares of Madrigal’s common stock, and in
the aggregate 11,796 time-based restricted stock units. All options
granted have an exercise price of $251.63 per share, and vest as
follows (i) 25% of the option shares will vest on the first
anniversary of the date of grant and (ii) 6.25% of the option
shares shall vest on each quarterly anniversary following the first
anniversary of the date of grant. All restricted stock units
granted vest in a 25% increment on each of the first through fourth
anniversaries of the grant date. All MSUs granted vest upon
certification concerning Madrigal’s stock price performance
measured against biotechnology stock index companies for the entire
performance period ending December 31, 2026. The vesting of all
awards described above shall be subject to each such employee’s
continued employment as of the vesting date.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a
clinical-stage biopharmaceutical company pursuing novel
therapeutics for nonalcoholic steatohepatitis (NASH), a liver
disease with high unmet medical need. Madrigal’s lead candidate,
resmetirom, is a liver-directed THR-β agonist oral therapy that is
designed to target key underlying causes of NASH. For more
information, visit www.madrigalpharma.com.
Investor Contact Tina Ventura,
Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates,
Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
過去 株価チャート
から 4 2024 まで 5 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
過去 株価チャート
から 5 2023 まで 5 2024